


Supplement Figure. The duration of treatments of chemotherapy and targeted therapies for patients with advanced HER2-mutant lung cancer.



HER2 TKI: afatinib, pyrotinib

Other TKI: gefitinib, icotinib, erlotinib, anlotinib

Chemotherapy: pemetrexed +/- platinum/bevacizumab, etoposide + platinum, gemcitabine+ platinum, docetaxel/taxane/vinorelbine/irinotecan +/- platinum/bevacizumab

→ : patient is still alive